Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

270 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse: a prospective West Japan hematology Study Group (W-JHS) NHL01 trial.
Kato K, Izutsu K, Nishikori M, Shibayama H, Maeda Y, Yoshimura K, Tateishi U, Miyamoto T, Matsuda Y, Ishikawa J, Rai S, Takahashi T, Yamauchi T, Matsumura I, Akashi K, Kanakura Y, Suzumiya J. Kato K, et al. Among authors: shibayama h. Int J Hematol. 2024 Jun;119(6):677-685. doi: 10.1007/s12185-024-03738-8. Epub 2024 Mar 22. Int J Hematol. 2024. PMID: 38519820 Clinical Trial.
Prognosis of patients with adult T-cell leukemia/lymphoma in Japan: A nationwide hospital-based study.
Imaizumi Y, Iwanaga M, Nosaka K, Ishitsuka K, Ishizawa K, Ito S, Amano M, Ishida T, Uike N, Utsunomiya A, Ohshima K, Tanaka J, Tokura Y, Tobinai K, Watanabe T, Uchimaru K, Tsukasaki K; for collaborative Investigators. Imaizumi Y, et al. Cancer Sci. 2020 Dec;111(12):4567-4580. doi: 10.1111/cas.14658. Epub 2020 Oct 21. Cancer Sci. 2020. PMID: 32976684 Free PMC article.
Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study.
Nakamura N, Arima N, Takakuwa T, Yoshioka S, Imada K, Fukushima K, Hotta M, Fuchida SI, Kanda J, Uoshima N, Shimura Y, Tanaka H, Ohta K, Kosugi S, Yagi H, Yoshihara S, Yamamura R, Adachi Y, Hanamoto H, Shibayama H, Hosen N, Ito T, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Hino M; Kansai Myeloma Forum. Nakamura N, et al. Among authors: shibayama h. Ann Hematol. 2024 Dec;103(12):5681-5690. doi: 10.1007/s00277-024-05705-z. Epub 2024 Mar 16. Ann Hematol. 2024. PMID: 38492020
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients.
Shimazu Y, Kanda J, Onda Y, Fuchida SI, Ohta K, Shimura Y, Kosugi S, Yamamura R, Matsuda M, Hanamoto H, Adachi Y, Anzai N, Hotta M, Fukushima K, Yagi H, Yoshihara S, Tanaka Y, Takakuwa T, Tanaka H, Shibayama H, Uoshima N, Hosen N, Ito T, Shimazaki C, Matsumura I, Kuroda J, Takaori-Kondo A, Hino M. Shimazu Y, et al. Among authors: shibayama h. Cancer Immunol Immunother. 2024 May 17;73(7):135. doi: 10.1007/s00262-024-03711-8. Cancer Immunol Immunother. 2024. PMID: 38758239 Free PMC article.
The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patients.
Shimazu Y, Kanda J, Takakuwa T, Onda Y, Fukushima K, Hotta M, Fuchida SI, Uoshima N, Shimura Y, Tanaka H, Ohta K, Shibayama H, Kosugi S, Yagi H, Yoshihara S, Hosen N, Ito T, Shimazaki C, Matsumura I, Kuroda J, Takaori-Kondo A, Hino M. Shimazu Y, et al. Among authors: shibayama h. Ann Hematol. 2024 Dec;103(12):5639-5649. doi: 10.1007/s00277-024-05934-2. Epub 2024 Aug 21. Ann Hematol. 2024. PMID: 39167179
Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study.
Izutsu K, Ando K, Nishikori M, Shibayama H, Goto H, Kuroda J, Kato K, Imaizumi Y, Nosaka K, Sakai R, Abe M, Hojo S, Nakanishi T, Rai S. Izutsu K, et al. Among authors: shibayama h. Int J Hematol. 2024 Nov;120(5):621-630. doi: 10.1007/s12185-024-03834-9. Epub 2024 Aug 23. Int J Hematol. 2024. PMID: 39179948 Free PMC article.
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR Investigators. Dimopoulos MA, et al. Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5. Lancet Oncol. 2016. PMID: 26671818 Free article. Clinical Trial.
ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone.
Kogure Y, Handa H, Ito Y, Ri M, Horigome Y, Iino M, Harazaki Y, Kobayashi T, Abe M, Ishida T, Ito S, Iwasaki H, Kuroda J, Shibayama H, Sunami K, Takamatsu H, Tamura H, Hayashi T, Akagi K, Shinozaki T, Yoshida T, Mori I, Iida S, Maeda T, Kataoka K. Kogure Y, et al. Among authors: shibayama h. Blood. 2024 Jun 6;143(23):2401-2413. doi: 10.1182/blood.2023022540. Blood. 2024. PMID: 38427753 Free article.
Primary analysis of a prospective cohort study of Japanese patients with plasma cell neoplasms in the novel drug era (2016-2021).
Shibayama H, Itagaki M, Handa H, Yokoyama A, Saito A, Kosugi S, Ota S, Yoshimitsu M, Tanaka Y, Kurahashi S, Fuchida SI, Iino M, Shimizu T, Moriuchi Y, Toyama K, Mitani K, Tsukune Y, Kada A, Tamura H, Abe M, Iwasaki H, Kuroda J, Takamatsu H, Sunami K, Kizaki M, Ishida T, Saito T, Matsumura I, Akashi K, Iida S. Shibayama H, et al. Int J Hematol. 2024 Jun;119(6):707-721. doi: 10.1007/s12185-024-03754-8. Epub 2024 Mar 29. Int J Hematol. 2024. PMID: 38548963 Free PMC article.
Differentiating Between Epstein-Barr Virus-positive Lymphoid Neoplasm Relapse and Post-transplant Lymphoproliferative Disorder After Sex-mismatched Hematopoietic Stem Cell Transplantation.
Kurashige R, Kurashige M, Okada Y, Higuchi K, Yuda S, Hino A, Miyamura T, Ichii M, Fukushima K, Honma K, Takeuchi M, Yokota T, Ishikawa J, Sawada A, Shibayama H, Hosen N, Morii E. Kurashige R, et al. Among authors: shibayama h. Am J Surg Pathol. 2024 Apr 1;48(4):395-405. doi: 10.1097/PAS.0000000000002183. Epub 2024 Jan 30. Am J Surg Pathol. 2024. PMID: 38287877
270 results